The new anti-TB drug, with delamanid as active substance, is currently administered to patients primarily children in the age group of six to 17 years in a few southern states of India and is yet to be introduced in Uttar Pradesh, which reported 4.22 lakh patients in 2018.
from Zee News :Zee News - Health http://bit.ly/2MK62X7
via IFTTT
No comments:
Post a Comment